95 related articles for article (PubMed ID: 32903131)
41. Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review.
Akram M; Tahir IM; Shah SMA; Mahmood Z; Altaf A; Ahmad K; Munir N; Daniyal M; Nasir S; Mehboob H
Phytother Res; 2018 May; 32(5):811-822. PubMed ID: 29356205
[TBL] [Abstract][Full Text] [Related]
42. Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19).
Khodadadi E; Maroufi P; Khodadadi E; Esposito I; Ganbarov K; Espsoito S; Yousefi M; Zeinalzadeh E; Kafil HS
Microb Pathog; 2020 Sep; 146():104241. PubMed ID: 32387389
[TBL] [Abstract][Full Text] [Related]
43. RNF90 negatively regulates cellular antiviral responses by targeting MITA for degradation.
Yang B; Liu Y; Cui Y; Song D; Zhang G; Ma S; Liu Y; Chen M; Chen F; Wang H; Wang J
PLoS Pathog; 2020 Mar; 16(3):e1008387. PubMed ID: 32126128
[TBL] [Abstract][Full Text] [Related]
44. Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials.
Arab-Zozani M; Hassanipour S; Ghoddoosi-Nejad D
BMJ Open; 2020 Jul; 10(7):e039730. PubMed ID: 32737100
[TBL] [Abstract][Full Text] [Related]
45. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
Azar MM; Shin JJ; Kang I; Landry M
Expert Rev Mol Diagn; 2020 Nov; 20(11):1087-1097. PubMed ID: 32990479
[TBL] [Abstract][Full Text] [Related]
46. Correction: comparing the expression levels of tripartite motif containing 28 in mild and severe COVID-19 infection.
Tavakoli R; Rahimi P; Hamidi-Fard M; Eybpoosh S; Doroud D; Ahmadi I; Anvari E; Aghasadeghi M; Fateh A
Virol J; 2022 Oct; 19(1):171. PubMed ID: 36316685
[No Abstract] [Full Text] [Related]
47. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.
Bhattacharyya A; Kumar S; Sarma P; Kaur H; Prajapat M; Shekhar N; Bansal S; Avti P; Hazarika M; Sharma S; Mahendru D; Prakash A; Medhi B
Indian J Pharmacol; 2020; 52(4):313-323. PubMed ID: 33078733
[TBL] [Abstract][Full Text] [Related]
48. Evasion of Type I Interferon by SARS-CoV-2.
Xia H; Cao Z; Xie X; Zhang X; Chen JY; Wang H; Menachery VD; Rajsbaum R; Shi PY
Cell Rep; 2020 Oct; 33(1):108234. PubMed ID: 32979938
[TBL] [Abstract][Full Text] [Related]
49. Virtual Trauma-Focused Therapy for Military Members, Veterans, and Public Safety Personnel With Posttraumatic Stress Injury: Systematic Scoping Review.
Jones C; Miguel-Cruz A; Smith-MacDonald L; Cruikshank E; Baghoori D; Kaur Chohan A; Laidlaw A; White A; Cao B; Agyapong V; Burback L; Winkler O; Sevigny PR; Dennett L; Ferguson-Pell M; Greenshaw A; Brémault-Phillips S
JMIR Mhealth Uhealth; 2020 Sep; 8(9):e22079. PubMed ID: 32955456
[TBL] [Abstract][Full Text] [Related]
50. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.
Huang AT; Garcia-Carreras B; Hitchings MDT; Yang B; Katzelnick LC; Rattigan SM; Borgert BA; Moreno CA; Solomon BD; Trimmer-Smith L; Etienne V; Rodriguez-Barraquer I; Lessler J; Salje H; Burke DS; Wesolowski A; Cummings DAT
Nat Commun; 2020 Sep; 11(1):4704. PubMed ID: 32943637
[TBL] [Abstract][Full Text] [Related]
51. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
Mojtabavi H; Saghazadeh A; Rezaei N
Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
[TBL] [Abstract][Full Text] [Related]
52. Herpes Zoster and Postherpetic Neuralgia in an Elderly Patient with Critical COVID-19: A Case Report.
Cao X; Zhang X; Meng W; Zheng H
J Pain Res; 2020; 13():2361-2365. PubMed ID: 33061551
[TBL] [Abstract][Full Text] [Related]
53. Degradation of SARS-CoV-2 receptor ACE2 by the E3 ubiquitin ligase Skp2 in lung epithelial cells.
Wang G; Zhao Q; Zhang H; Liang F; Zhang C; Wang J; Chen Z; Wu R; Yu H; Sun B; Guo H; Feng R; Xu K; Zhou G
Front Med; 2021 Apr; 15(2):252-263. PubMed ID: 33511555
[TBL] [Abstract][Full Text] [Related]
54. The Functions of TRIM56 in Antiviral Innate Immunity and Tumorigenesis.
Fu L; Zhou X; Jiao Q; Chen X
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902478
[TBL] [Abstract][Full Text] [Related]
55. TRIM56 acts through the IQGAP1-CDC42 signaling axis to promote glioma cell migration and invasion.
Zhang Q; Zheng J; Wu W; Lian H; Iranzad N; Wang E; Yang L; Wang X; Jiang X
Cell Death Dis; 2023 Mar; 14(3):178. PubMed ID: 36870986
[TBL] [Abstract][Full Text] [Related]
56. TRIM56 promotes malignant progression of glioblastoma by stabilizing cIAP1 protein.
Yang X; Zhang Y; Xue Z; Hu Y; Zhou W; Xue Z; Liu X; Liu G; Li W; Liu X; Li X; Han M; Wang J
J Exp Clin Cancer Res; 2022 Dec; 41(1):336. PubMed ID: 36471347
[TBL] [Abstract][Full Text] [Related]
57. TRIM56 positively regulates TNFα-induced NF-κB signaling by enhancing the ubiquitination of TAK1.
Liu Y; Chen Y; Ding C; Zhu X; Song X; Ren Y; Wang Q; Zhang Y; Sun X
Int J Biol Macromol; 2022 Oct; 219():571-578. PubMed ID: 35952808
[TBL] [Abstract][Full Text] [Related]
58. Impaired Antiviral Responses to Extracellular Double-Stranded RNA and Cytosolic DNA, but Not to Interferon-α Stimulation, in TRIM56-Deficient Cells.
Wang D; Wang R; Li K
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062293
[TBL] [Abstract][Full Text] [Related]
59. Cytoplasmic NEAT1 Suppresses AML Stem Cell Self-Renewal and Leukemogenesis through Inactivation of Wnt Signaling.
Yan H; Wang Z; Sun Y; Hu L; Bu P
Adv Sci (Weinh); 2021 Nov; 8(22):e2100914. PubMed ID: 34609794
[TBL] [Abstract][Full Text] [Related]
60. Identification of TRIM56 as a Potential Biomarker for Lung Adenocarcinoma.
Lu K; Sui Y; Fu L
Cancer Manag Res; 2021; 13():2201-2213. PubMed ID: 33707970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
